ABSTRACT. IJMDS January 2017; 6(1) 1357

Similar documents
Original Article. Abstract INTRODUCTION. Key words: Adherence, antidiabetic drugs, diabetic outpatients, drug utilization

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes

PRESCRIBING PATTERN OF ANTIDIABETIC DRUGS IN TYPE-2 DIABETIC PATIENTS

WHO Guidelines for Management of Diabetes in Low Resource Settings

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes

Prescribing pattern and efficacy of anti diabetic drugs in maintaining optimal glycemic levels in diabetic patients

Rajiv Gandhi University of Health Sciences

Guideline for antihyperglycaemic therapy in adults with type 2 diabetes

STUDY OF DRUG UITLIZATION PATTERN OF ANTIHYPERTENSIVE DRUGS IN HYPERTENSIVE NEPHROPATHY IN A TERTIARY CARE TEACHING HOSPITAL, BAREILLY, U.P.

IJBCP International Journal of Basic & Clinical Pharmacology

Adepu and Adusumilli: Drug-related Problems in Patients with Chronic Diseases in South India

International Journal of Research in Pharmacology & Pharmacotherapeutics

Treatment Options for Diabetes: An Update

International Journal of Medicine and Pharmaceutical Research

Management of Type 2 Diabetes

Assessment of Medication-Related Problems in Geriatric Patients of a Rural Tertiary Care Hospital

DIABETES AND RAMADAN FASTING

Indian Journal of Basic and Applied Medical Research; June 2014: Vol.-3, Issue- 3, P

Newer Drugs in the Management of Type 2 Diabetes Mellitus

COMPARATIVE STUDY ON DUAL AND TRIPLE THERAPY USING ORAL ANTIDIABETIC DRUGS IN TREATMENT OF TYPE 2 DIABETES MELLITUS

A prospective study on drug utilization pattern & rationality in treatment of type II diabetes mellitus: a population based analysis

Wayne Gravois, MD August 6, 2017

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function

Drugs used in Diabetes. Dr Andrew Smith

Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy

PERIOPERATIVE DIABETES GUIDELINE

YOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013

Management of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control

DIA LEAGUE DIA LEAGUE. 06 th November, Chandigarh, India

Dept of Diabetes Main Desk

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

Cost Effectiveness of canagliflozin (Invokana )

STUDY OF DRUG USE EVALUATION ON ORAL ANTIHYPERGLYCEMIC AGENTS IN TYPE 2 DIABETES MELLIITUS AND THEIR POTENTIAL DRUG-DRUG INTERACTIONS

How can we improve outcomes in Type 2 diabetes?

Screening of Type II Diabetes Mellitus on the Basis of IDRS Among Urban Population of Bhopal, Madhya Pradesh

Index. Note: Page numbers of article titles are in boldface type.

IJBCP International Journal of Basic & Clinical Pharmacology

National Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes

International Journal of Advancements in Research & Technology, Volume 2, Issue 6, June-2013 ISSN

Clinical Guidelines. Management of adult patients with diabetes undergoing endoscopic procedures

Canagliflozin in combination therapy for treating type 2 diabetes

Diabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Sudhir Singh Gangwar et al. Int. Res. J. Pharm. 2014, 5 (4) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

National Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008

Diabetes Mellitus. Medical Management and Latest Developments Dr Ahmad Abou-Saleh

Oral and Injectable Non-insulin Antihyperglycemic Agents

Prevalence of pre-diabetes among the general population in a tertiary care hospital in north India

The session was open with an introductory session by Asian Society of continuing Medical Education and followed by the scientific agenda.

Comparative Effectiveness and Safety of Diabetes Medications for Adults with Type 2 Diabetes

Department of Pharmacy Practice, KVSR Siddhartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, INDIA. 2

Type Two Diabetes Mellitus Prescribing in New Zealand - What are we dispensing?

Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control

Patients characteristics associated with better glycemic response to teneligliptin and metformin therapy in type 2 diabetes: a retrospective study

DPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes

SIGNIFICANCE OF PATIENT COUNSELING IN DIABETES MELLITUS; A PROSPECTIVE STUDY

Assessment of cardiovascular risk among diabetic patients in an urban area of Kancheepuram district, India: a cross sectional study

Diabetes mellitus. Treatment

Profile of diabetes mellitus in elderly of Chandigarh, India. S Puri, M Kalia, H Swami, A Singh, Abhimanyu, C Mangat, A Kaur, S Kaur

9 Diabetes care. Back to contents

Glucose Control drug treatments

What s New on the Horizon: Diabetes Medication Update

Diabetes Medications: Oral Anti-Hyperglycemic Medications

TRANSPARENCY COMMITTEE OPINION. 29 April 2009

DIA LEAGUE DIA LEAGUE. 26 th November, Bhubaneshwar, India

International Journal of Health Sciences and Research ISSN:

A Guidance Statement from the American College of Physicians

UK launch of once-daily tablet from Janssen provides new option to improve blood glucose control for thousands of people with Type 2 diabetes 1

Scottish Medicines Consortium

MOA: Long acting glucagon-like peptide 1 receptor agonist

Diabetes Management and Considerations for the Indian Culture

Polytechnic Institute of Coimbra, Coimbra Health School, Pharmacy, Portugal 2

Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care

SCIENTIFIC STUDY REPORT

Supplementary Online Content

Cardiovascular Health and Diabetes Screening for People with Schizophrenia

Original Article. Gautam A.G 1, Bansal P 2, Chauhan R 3, Chadha V 4 NTRODUCTION

Fasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period

Prevalence of Potentially Inappropriate Medications among Geriatric Diabetes Mellitus Patients and Prescription Pattern at a Tertiary Care Hospital

SIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION

CASE A2 Managing Between-meal Hypoglycemia

Diabetes in Pregnancy

What s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA

Knowledge, attitude and practices of type II diabetes mellitus patients in a tertiary care teaching institute of central India

IJBCP International Journal of Basic & Clinical Pharmacology

Julie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education

Focus on diabetes mellitus - A review. Saravanan K * and Manna PK. Department of pharmacy, Annamalai university, Annamalai Nagar, Tamilnadu, India

Non-insulin treatment in Type 1 DM Sang Yong Kim

Antihypertensive Drugs Prescribing Pattern in Patients Attending to Medicine Outpatient Department

Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016

Diabetes Mellitus. Raja Nursing Instructor. Acknowledgement: Badil 09/03/2016

Supplementary Online Content

3. NEW DIAGNOSTIC CRITERIA, NEW CLASSIFICATION OF DM AND MODERN THERAPY APPROACH

CADTH Optimal use report

Alia Gilani Health Inequalities Pharmacist

Elements for a public summary

Effect of bitter gourd clinical trial in prediabetics: blind, randomised, cross over trial in India

dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca

Soliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)

Navigating the New Options for the Management of Type 2 Diabetes

Transcription:

Original Article A drug utilisation study of antihyperglycaemic agents in a rural tertiary care hospital Naidu CDM 1, Vardhan A 2, Bankar MA 3, Sharma S 4, Raghuvanshi VS 5, Reddy S 6 1 Dr C Dinesh M Naidu Professor drcdineshnaidu@gmail.com 2 Dr Anand Vardhan varanand.26@gmail.com 3 Dr Mangesh Bankar Associate Professor drmangesh_bankar@yahoo.co.in 4 Dr Sagar Sharma sagar87sharma@gmail.com 5 Dr Vinay Singh Raghuvanshi drvinaysraghu@gmail.com 1,2,3,4,5 Department of Pharmacology Andaman and Nicobar Islands Institute of medical sciences Port blair, India 6 Dr Srinivas Reddy Senior resident Department of medicine Kamineni Institute of Medical Sciences Narketpally, Telangana, India Received: 29-09-2016 Revised: 10-10-2016 Accepted: 04-11-2016 Correspondence to: Dr Anand Vardhan varanand.26@gmail.com ABSTRACT Background: Diabetes mellitus is an emerging non communicable, life style disease. The aim was to evaluate the drug utilization pattern of anti-diabetic drugs in diabetic outpatients and monitor the adverse drug reactions (ADRs) associated with anti-diabetic therapy. Materials and methods: A prospective observational study was carried out in adult diabetic patients from the Department of General Medicine of a rural tertiary care hospital in October 2013- December 2014 after obtaining written informed consent from the patient and approval from institutional ethics committee. Demographic data, drug utilization pattern, cost of the antidiabetic drugs along with defined daily dose was calculated. ADRs due to anti-diabetic drugs were summarized. Results: A total of 450 patients were enrolled in the study of which there was male preponderance and majority belong to geriatric age. The most common comorbidity was hypertension. Insulin was most commonly prescribed drug during hospital stay and metformin at the time of discharge. Of the combination therapy dual therapy of metformin and glimipiride was most preferred. The total antihyperglycaemic drug consumption was 15.65 DDD/ 100 bed days. 67 ADR were reported of which the most common was hypoglycaemia. Conclusions: The study showed insulin and metformin were the most commonly used drugs. The prescribing trend also appears to be moving towards combination therapy particularly two drug therapies. The most commonly reported ADR was hypoglycaemia. Keywords: Drug utilization, anti-diabetic drugs, adverse drug reactions, DDD Introduction Diabetes is a chronic disorder defined as metabolic cum vascular syndrome of multiple etiology characterized by chronic hyperglycemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both leading to changes in both small blood vessels (Microangiopathy) and large blood vessels (Macroangiopathy). Diabetes mellitus is the most common metabolic disorder in the world. According to the International Diabetes Federation 387 million people in the world live with diabetes as of 2014. [1] In most countries the number of individuals with diabetes is steadily increasing. According to WHO, around 31.7 million Indians are effected by diabetes by 2000 and it is estimated that it may increase to 79.4 million by 2030. [2] Management of diabetes includes both pharmacological treatments like insulins and oral hypoglycaemic agents as well as nonpharmacological management like diet modification and life-style changes. The oral hypoglycaemic agents include sulfonylureas (glibenclamide), biguanides (metformin), thiazolidinediones (pioglitazone), alpha glucosidase inhibitors (acarbose), meglitinides (repaglinide), GLP-1 analogues (exenitide), DPP 4 inhibitors (sitagliptin), SGLT 2 inhibitors (dapaglifozin). [3] Drug utilisition is defined by WHO as the marketing, distribution, prescription IJMDS www.ijmds.org January 2017; 6(1) 1357

and use of drugs in a society, with special emphasis on the resulting medical, social and economic consequences (WHO, 1977). [4] These studies play a crucial role in making essential drug list, understanding current drug prescribing practices and also identifying irrational prescribing of drugs. In this context the present study was undertaken to analyse the prescription pattern of antidiabetic agents during the hospital stay and at the time of discharge with relevance to economic burden and adverse drug monitoring in a tertiary care teaching hospital. Material and methods This prospective observational study was conducted over a period of 6 months in the inpatient department of General Medicine at Kamineni Institute of Medical Sciences, a tertiary care teaching hospital. The study was approved by the Institutional Ethics Committee. Informed consent was taken from the subjects prior to the study. Patients of both sex and age ranging from 16 to 65 years were included in the study. Newly diagnosed and known cases of diabetes with co morbidities were also included in the study. Patients with gestational diabetes mellitus and type 1 diabetes mellitus were excluded from the study. Patient data was recorded in the standard case record form. Cost of therapy was assessed using total cost of the antidiabetic drug per patient and expressed as mean ± SEM. Defined daily dose was calculated using the formula severity of ADR was categorized as mild, moderate, severe or lethal as per modified Hartwig scale. The causality assessment of ADRs was done as per Naranjo scale into definite, possible, probable and doubtful. Results Total enrolled patients were 450 of which 261(58%) are male and 189 (42%) are female. (Fig 1) Mean age of the patients was 62.8± 2.3 years. Comorbid conditions were found in 369 patients of which hypertension was most common. Other co-morbid conditions include diabetic nephropathy, diabetic neuropathy, acute urinary tract infections, respiratory tract infections, frozen shoulder and thyroid disorders (Fig 2). Average number of antidiabetic medicines per prescription according to WHO core drug prescribing indicators was 1.8 (Table 1). Drugs prescribed by generic name were only 12.2% and percentage of drugs prescribed from essential drug list was 78.3%. Fig 1: Sex distribution of the patients DDD/100 bed days = Drug consumed(mg) during study period x 100 DDD(mg) x period of study x bed strength x average occupancy Average occupancy was calculated by dividing number of occupied beds by total number of beds in medicine ward. The adverse drug reactions (ADRs) related to anti-diabetic drugs were monitored and documented in suitably designed ADR monitoring forms. The severity and causality of the ADR were also assessed. The Fig 2: Incidence of co-morbidities Insulin was most commonly prescribed anti hyperglycaemic agent during the stay (76%) and IJMDS www.ijmds.org January 2017; 6(1) 1358

metformin was the most common at the time of discharge (82%) (Fig 3). Usuage of insulin was reduced by around 30% from hospital stay to the time of discharge and use of metformin has increased by 12% followed by glimipiride (8%). Of the insulins the most common prescribed form was combination of basal insulin and human insulin both during hospital stay and at discharge. Combination therapy of 2 drugs was most commonly prescribed of which metformin with glimiperide is more often given. Triple therapy was less preferred and most commonly added 3 rd drug was insulin. 4 drug regimen was given to only 1 patient during hospital stay and to 6 patients while discharge. The drug added to 4 drug regimen was voglibose during hospital stay and sitagliptin during discharge. The average cost, as expressed in mean ± SD, of anti-diabetic drugs during the hospital stay was Rs. 112.80 ± 34.58 and at the time of discharge was Rs.95.76 ± 54.32. Drug consumption was calculated in defined daily dose (DDD) per 100 bed days. The total drug consumption for anti hyperglycaemic agents was 15.65 DDD/100 bed days (Table 2). The highest DDD was for insulin which was 10.65 and the lowest was for sitagliptin which was not prescribed during hospital stay. The drugs were classified according to Anatomical therapeutic chemical classification and their DDD/100 bed days are tabulated below. During the study period, 67 subjects had adverse drug reaction of which the most common being hypoglycaemia(64). 1 developed loose stools and 2 patients developed flatulence. More females developed hypoglycaemia than males and is observed often in the age group of more than 65 years. Incidence was highest among diabetics with more than one co-morbidity. All reactions were mild/ moderate according to Hartwig scale. In the causality assessment according to Naranjo scale, all belong to probable category. Table 1: WHO core prescribing indicators applicable to the study S.no. Indicator Value 1 Average number of anti diabetic drugs per encounter 2 Percentage of drugs prescribed by generic name 3 Percentage of encounters with injection 4 Percentage of drugs prescribed from essential drug list 1.8 21.2% 80.8% 78.3%. Fig. 3 Prescription pattern of drugs at hospital stay and at discharge Table 2: ATC classification and DDD of the drugs S.No. Drug ATC classification DDD/100 bed days 1 Insulin( regular) A10AD01 10.65 2 Insulin( basal) 3.89 3 Metformin A10BA02 0.87 4 Glimiperide A10B12 0.54 5 Glibenclimide A10BB01 0.21 6 Acarbose A10BF01 0.06 7 Voglibose 0.12 8 Pioglitazone A10BG03 0.01 9 Sitagliptin 0.00 IJMDS www.ijmds.org January 2017; 6(1) 1359

Table 3: ADR relation with sex, age, co-morbid conditions and duration of diabetes Characteristics Number of patients Patients with ADR Sex Male 261 24 Female 189 43 Age More than 65 years 285 52 Less than 65 years 165 15 Co-morbidities 1 co-morbidity 323 23 More than 1 co-morbidity 127 44 Duration of Diabetes Less than 5 years 221 18 More than 5 years 229 49 Discussion Out of the 450 patients who are enrolled the majority are male and belong to geriatric age group showing male preponderance in diabetes. This is in comparison to other studies done in India. [5,6] The most common co-morbid condition was hypertension which is similar to study done by Abdi SH etal,2012 and Arauz-Pacheco etal,2002. [6,7] The present study revealed that the most common drug to be prescribed at the time of discharge was metformin but during the stay was insulin. Average number of anti-diabetic drugs 1.8 which is less than study done by Sultana G [8] etal, 2010. The percentage of diabetics receiving insulin during the hospital stay was higher than the study done by Sultana G etal, 2010 [8] but less than Abdi SH etal, 2012. [6] The combination of metformin with glimipiride was most commonly used dual therapy according to the present study which was comparable to other studies. [9] In the study by Kumar et al, insulin + metformin (16.6%) was the most prescribed antidiabetic combination followed by glimepiride + metformin (10%). [10] Though there were multiple newer drugs their use was restricted mainly due to higher cost and lack of data on prolonged usage. The average cost of anti diabetic drugs during the hospital stay was Rs. 112.80 ± 34.58 and at the time of discharge was Rs.95.76 ± 54.32 for 450 patients according to DDD concept. DDD is assumed average maintenance dose per day for a drug used for its main indication in adults. Highest DDD was for regular insulin which was 10.65 and overall anti hyperglycaemic drugs was 15.65 DDD/ 100 beds. During the present study, 67 adverse effects were reported in which there was female preponderance. Adverse effects were more common among geriatric age group and in subjects with multiple comorbidities. Duration of diabetes played a significant role in development of ADR as subjects having diabetes or more than 5 years are most commonly treated with dual or triple regimen leading to the adverse reaction of hypoglycaemia (Table 3). Metformin was the most commonly used drug at discharge and insulin was the most common during the hospital stay. The trend towards dual therapy was increasing showing strict control of glycaemic status. The use of newer drugs was highly restricted. Incidence of ADR particularly hypoglycaemia was high among geriatrics and combination therapy patients. References 1. IDF Diabetes Atlas. 6 th ed. International Diabetes Federation, 2013. Available from: http://www.idf.org. Accessed on 10 october 2016. IJMDS www.ijmds.org January 2017; 6(1) 1360

2. Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R, et al. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study. Diabetologia 2011;54:3022-27. 3. Unger J. Current strategies for evaluating, monitoring, and treating type 2 diabetes mellitus. Am J Med 2008;121(6 Suppl):S3-8. 4. Lee D, Bergman U. Studies of drug utilization. In: Strom BL, editor. Pharmacoepidemiology. 4 ed. New York: John Wiley & Sons; 2005.p. 401. 5. Vengurlekar S, Shukhla P, Patidar P, Bafna R, Jain S. Prescribing pattern of anti-diabetic drugs in Indore city hospital. Indian J Pharm sci 2008;70:637-40. 6. Abdi SH, Churi S, Ravi Kumar YS. Study of drug utilization pattern of antihyperglycaemic agents in South Indian tertiary care teaching hospital. Indian J Pharmacol Sci 2102;44:210-14. 7. Arauz-Pacheco, Parrott MA, Raskin P. Treatment of hypertension in patients with diabetes. Diabetes care 2002;25:134-7. 8. Sultana G, Kapur P, Aqil M, Alam MS, Pillai KK. Drug utilisation of oral hypoglycaemic agents in university teaching hospitals in India. J Clin Pharm Ther 2010;35:267-77. 9. Lau GS, Chan JS, Chu PL, Tse DC, Critchely JA. Use of antidiabetic and anti hypertensive drugs in hospital and outpatient settings in Hong kong. Ann Pharmacother 1996;30:232-7. 10. Kumar KS, Sreeramya G, Krishna KM, Nalini K, Kiranmai N, Vasavi P. Drug use pattern study of antidiabetics in type 2 diabetes mellitus at a tertiary care hospital in Tenali, Andhra Pradesh. Int J Inv Pharm Sci 2013;1:162-6. Cite this article as: Naidu CDM, Vardhan A, Bankar M, Sharma S, Raghuvanshi V, Reddy S. A drug utilisation study of antihyperglycaemic agents in a rural tertiary care hospital. Int J Med and Dent Sci 2017;6(1):1357-1361. Source of Support: Nil Conflict of Interest: No IJMDS www.ijmds.org January 2017; 6(1) 1361